SIBN (SI-BONE) Cash And Cash Equivalents : $30.2 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is SI-BONE Cash And Cash Equivalents?

SI-BONE's quarterly cash and cash equivalents declined from Mar. 2024 ($32.04 Mil) to Jun. 2024 ($25.58 Mil) but then increased from Jun. 2024 ($25.58 Mil) to Sep. 2024 ($30.23 Mil).

SI-BONE's annual cash and cash equivalents declined from Dec. 2021 ($63.42 Mil) to Dec. 2022 ($20.72 Mil) but then increased from Dec. 2022 ($20.72 Mil) to Dec. 2023 ($33.27 Mil).

SI-BONE Cash And Cash Equivalents Historical Data

The historical data trend for SI-BONE's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SI-BONE Cash And Cash Equivalents Chart

SI-BONE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

10.44

53.58

63.42

20.72

33.27

SI-BONE Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash And Cash Equivalents	Get a 7-Day Free Trial															53.49	33.27	32.04	25.58	30.23

SI-BONE Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

SI-BONE (NAS:SIBN) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

SI-BONE Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of SI-BONE's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

SI-BONE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SI-BONE Inc (NAS:SIBN) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

471 El Camino Real, Suite 101, Santa Clara, CA, USA, 95050

Website

https://www.si-bone.com

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

Executives

Anthony J Recupero	officer: Chief Commercial Officer	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Anshul Maheshwari	officer: Chief Financial Officer	471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Laura Francis	officer: Chief Financial Officer	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Jeffrey W Dunn	director, officer: Chairman, President & CEO	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Mika Nishimura	director	471 EL CAMINO REAL, SANTA CLARA CA 95050
Davis Timothy E Jr	director	5677 AIRLINE ROAD, ARLINGTON TN 38002
John Gordon Freund	director, 10 percent owner	125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Jeryl L Hilleman	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Michael A Pisetsky	officer: GC & Chief Compliance Officer	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Karen A Licitra	director	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Helen Loh	director	471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Skyline Venture Partners V Lp	10 percent owner	525 University Avenue, Suite 520, Palo Alto CA 94301
W Carlton Reckling	officer: CMO and VP, Medical Affairs	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Scott A Yerby	officer: Chief Technology Officer	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Heyward R Donigan	director	452 DISCOVERY ROAD, VIRGINIA BEACH VA 23451